Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HEXA | P06865 | 7/20 | 0.70 |
| ▸ | HEXB | P07686 | 7/20 | 0.70 |
| ▸ | DHFR | P00374 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049489 | 0.88 | HEXA (0.62) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL29913197 | 0.85 | HEXA (0.59) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL12368255 | 0.83 | HEXA (1.00) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL29913218 | 0.82 | HEXA (0.64) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL6049555 | 0.79 | DHFR (0.64) | HEXAHEXBDHFRMEN1ALDH1A1 | |
| SCHEMBL3498787 | 0.77 | HEXA (1.00) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL5069251 | 0.76 | HEXA (0.48) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL9765076 | 0.76 | HEXA (0.62) | HEXAHEXBDHFRCYP2D6REN | |
| Water SCHEMBL9765099 | 0.75 | HEXA (0.60) | HEXAHEXBDHFRCYP2D6NCOA1 | |
| Pyrimethamine SCHEMBL15516970 | 0.74 | HEXA (1.00) | HEXAHEXBDHFRMEN1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235012-A1 | ACID ADDITION SALT OF PYRIMETHAMINE | GLG PHARMA S A (PL) | 2022-07-28 | — | — | US | disclosed |
| CN-112513018-A | Acid addition salts of pyrimethamine | GLG制药有限责任公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3788034-A1 | ACID ADDITION SALT OF PYRIMETHAMINE | GLG Pharma S.A. (PL) | 2021-03-10 | — | — | EP | disclosed |
| WO-2019182463-A1 | ACID ADDITION SALT OF PYRIMETHAMINE | GLG Pharma S.A. (PL) | 2019-09-26 | — | — | WO | disclosed |
| EP-1681058-A2 | Pharmacologically active cns compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2006-07-19 | — | — | EP | disclosed |
| EP-1325916-A1 | Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system | THE WELLCOME FOUNDATION LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| CN-1066720-C | Process for preparing compounds having pharmacological activity on the central nervous system | WELLCOME FOUND (GB) | 2001-06-06 | — | — | CN | disclosed |
| CN-1066719-C | Process for preparing compounds having pharmacological activity on the central nervous system | WELLCOME FOUND (GB) | 2001-06-06 | — | — | CN | disclosed |
| US-5712276-A | TREATING NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1998-01-27 | — | — | US | disclosed |
| US-5684005-A | PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE | GLAXO WELLCOME INC. (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0727214-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0715851-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-12 | — | — | EP | disclosed |
| EP-0713703-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-29 | — | — | EP | disclosed |
| CN-1117046-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1996-02-21 | — | — | CN | disclosed |
| CN-1115756-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1996-01-31 | — | — | CN | disclosed |
| CN-1113487-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1995-12-20 | — | — | CN | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| CN-1052306-A | Compounds having pharmacological activity on the central nervous system | WELLCOME FOUND (GB) | 1991-06-19 | — | — | CN | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |
| US-3728452-A | WATER-SOLUBLE COMPOSITION COMPRISING SULFADIMIDINE AND PYRIMETHAMINE | ABIC LTD | 1973-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235012-A1 | ACID ADDITION SALT OF PYRIMETHAMINE | TPMT, DPYD, APRT | HEXA 1003/4885HEXB 2104/4885DHFR 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.